TIDMAKR
RNS Number : 4834H
Akers Biosciences, Inc.
18 August 2016
Akers Biosciences, Inc.
Results of OxiChek Test Study
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the
"Company" or "Akers Bio"), a developer of rapid health information
technologies, announces the results of a study of the Company's
BreathScan OxiChek(TM) test ("OxiChek(TM)"), the first disposable
breath test to rapidly determine levels of oxidative stress in the
body - an indicator of the overall health and wellbeing of a
person.
The study was performed in Philadelphia, PA, under the
supervision of Adam C. Sobel M.D., Director, Medical of Akers Bio.
The results were highly successful with a correlation between
OxiChek(TM) and the standard reference laboratory blood testing
method (TBARS) of 99.5%. The study demonstrated a reproducibility
of 100%, meaning the test results from the same lung simulator had
zero variation after multiple repeats. The study further
demonstrated an intra-subject variation ranging from 1.61% to
14.87%, indicating a narrow variation upon multiple repeat tests by
the same human subject.
OxiChek(TM) is a general wellness product from Akers
Wellness(TM), intended to measure indicators of oxidative stress in
exhaled breath. Unlike current laboratory testing methods that test
only a few free radicals using an invasive blood draw - and have a
turnaround time of 7 to 10 days - Akers Bio's rapid OxiChek(TM)
test detects a broad spectrum of free radicals contained in a
person's exhaled breath in just a few minutes.
OxiChek(TM) works with BreathScan Lync(TM), the new
bluetooth-enabled reading device from Akers Wellness(TM), to enable
users to track their results via a mobile device. It can be used to
promote, track and/or encourage choices, such as use of nutritional
supplements which, as part of a healthy lifestyle, may help to
reduce the risk of certain chronic diseases or conditions.
Raymond F. Akers, Jr. PhD, Co-founder and Chief Scientific
Director of Akers Bio, said: "Once again a study has demonstrated
an exceptionally high correlation between an Akers Bio rapid breath
test and an established reference laboratory blood test. This
further underpins the value which we believe lies within our
proprietary breath testing technology which we have always believed
would very closely mirror blood testing for certain biomarkers.
"We are very excited about these particular study results for
OxiChek(TM). Not only do they demonstrate the effectiveness of our
test for oxidative stress, but the comparison to the standard
reference laboratory test - blood vs breath - is remarkable. Add to
this the results of an earlier study that showed a significant
correlation between OxiChek(TM) results and the age of the test
subjects, and we believe that we have a powerful tool for the
expansive health and wellness and anti-aging industry."
John J. Gormally, Chief Executive Officer of Akers Bio, added:
"I am delighted with the outcome of this study. Our work in
demonstrating the efficacy of the OxiChek(TM) test strongly
underpins the commercialization strategy for this exciting new
product from Akers Bio. We have just begun selling OxiChek(TM)
through our recently appointed distributor Aero-Med, which is
targeting the anti-aging, functional and integrative health and
wellness treatment practitioner market in the US; and we are also
in active discussions with other distribution partners for
OxiChek(TM) with capabilities within other target markets."
BreathScan OxiChek(TM) and other Akers Bio health and wellness
tests do not require US FDA clearance and are being marketed now in
the US and other territories covered by the Company's international
distribution network.
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
The information communicated in this announcement is inside
information for the purposes of Article 7 of Regulation
596/2014.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Co-founder and Chief Scientific Director
Tel. +1 856 848 8698
Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Email: cs@taglichbrothers.com
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9704
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBLGDIXXBBGLR
(END) Dow Jones Newswires
August 18, 2016 02:00 ET (06:00 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2023 to Mar 2024